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Inducible NPM-ALK silencing leads to cell cycle arrest and apoptosis in 
vitro and tumor growth regression in vivo. Using a lentivirus-medi-
Figure 1
Inducible NPM-ALK knock down leads to apoptosis of ALCL cells and tumor regression in vivo. (A) Conditional expression of the shRNA internal 
marker gene GFP. TS cells cotransduced with pLV-tTR-KRAB/DsRed and pLVTH-ALK-A5/GFP (TS A5, right) or with the mutated pLVTH-ALK-
A5M/GFP (TS A5M, left) lentiviral preparations were cultured with doxycycline (DOX) (1 μg/ml) for the indicated times and subsequently analyzed 
by flow cytometry (72 hours). (B) Kinetics of NPM-ALK knock down. TS-TTA-A5 cells were treated with DOX and harvested at the indicated 
times. Whole-cell lysates were analyzed by Western blotting with anti-GFP or ALK antibodies. (C and D) Inducible NPM-ALK knock down leads 
to downmodulation of ALK and of known downstream targets in TS-TTA-A5 cells. (C) RNA levels of NPM-AlK, CD30 (TNFRSF8), and β2-micro-
globulin transcripts were determined by semiquantitative RT-PCR (72 hours). (D) Protein expressions were assayed by Western blotting with 
the specified antibodies (72–84 hours). (E and F) Loss of NPM-ALK leads to G1 cell-cycle arrest and apoptosis. TS-TTA-A5 or -A5M cells were 
harvested after DOX induction and analyzed by flow cytometry. (E) The percentage of cells in G0/G1, S, and G2-M phases was determined by 
PI staining (96 hours). (F) The fraction of apoptotic cells was assayed by annexin V staining (120 hours). (G) NPM-ALK ablation induces tumor 
regression in vivo. Representative tumor growth curves for TS-TTA-A5 cells injected subcutaneously into BNX mice in an untreated mouse 
(green) or 2 mice treated for 14 days with DOX (red) starting at day 17. Each data point represents the average diameter of 2 tumor masses. 
Similar results were obtained from 9 mice injected with TS-TTA-A5 cells, with slightly differing kinetics.
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NPM-ALK gene expression signature in 
ALCL cells derived by inducible shRNA. 
(A) GEP differentiates ALCL cells based 
on ALK expression. Unsupervised anal-
ysis of TS-TTA-A5, TS-TTA-A5M, and 
Su-DHL1-TTA-A5 cells untreated or 
treated with DOX for the indicated times. 
In the matrix, each column represents a 
sample, and each row a gene. The 21 
samples were grouped according to the 
expression levels of the 267 most vari-
able genes, after removal of the signals 
whose expression levels did not vary 
across experimental conditions. The 
color scale bar represents relative gene 
expression changes, normalized by the 
standard deviation. (B) The supervised 
analysis identified a selected number of 
genes specifically modified in untreated 
versus treated TS-TTA-A5 cells. Cell 
samples were cultured with (n = 6) and 
without (n = 6) DOX for the indicated 
times. The expression pattern of the 
identified genes in TS-TTA-A5M cells 
treated with DOX (84 hours) is shown 
on the right side. DEG, differentially 
expressed genes. (C) Functional strati-
fication of ALK-regulated genes. Genes 
differentially expressed in TS-TTA-A5 
treated with DOX were grouped accord-
ing to their functional categories.
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BCL2A1 expression is regulated by NPM-ALK activity and sustains the 
survival of ALK-positive ALCL cells. To dissect the biological prop-
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Figure 3
Generation and validation of a restricted signature for ALK-positive ALCL cells. (A) Kinetics of NPM-ALK dephosphorylation and CD30 
(TNFRSF8) downregulation determined by ALK inhibitors. ALK-positive cells were treated (300 nM) with A1 (CEP-11988) or A2 (CEP-14083) 
as indicated. ALK phosphorylation was assayed using a specific phospho-ALK (Y1604) antibody (upper panels). Levels of TNFRSF8 and 
β2-microglobulin mRNA were analyzed by semiquantitative RT-PCR (lower panels). (B) Gene expression profiling differentiates ALCL cells based 
on ALK activity. Unsupervised analysis of TS-TTA-A5 cells after no treatment (U) or treatment with A1, A2, or A3 (CEP-14513) ALK inhibitors 
(6 hours). In the matrix, each column represents a sample and each row a gene. The 12 samples were grouped in the dendrogram accord-
ing to the expression levels of the 320 most variable genes. (C) ALK inhibitors modulate a similar set of genes. Number of genes differentially 
expressed in TS-TTA-A5 following ALK kinase inhibition as determined by supervised analysis for the indicated conditions. (D) Eisen plot of the 
expression values of 52 transcripts consistently modulated across shRNA- and ALK inhibitor-treated TS-TTA-A5 cells. (E) RT-PCR validation of 
NPM-ALK signature. A5- or A5M-transduced TS-TTA and Su-DHL1-TTA cells were treated with DOX for 72 hours, and mRNA expression for 6 
genes (ICOS, RGS16, CCl20, DKC1, GNl3, BCl2A1) was determined by semiquantitative RT-PCR.
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BCL2A1 expression is regulated by NPM-ALK activity and sustains the survival of ALK-positive ALCL cells. (A and B) BCL2A1 shRNA induces 
apoptosis of ALCL cells. (A) TS cells were transduced with lentivirus (pLKO-GFP) expressing 4 BCL2A1-directed shRNAs (2A–D). BCl2A1 
mRNA expression was determined by RT-PCR analysis (72 hours). (B) TS cells were transduced with a mock or a BCL2A1-directed shRNA 
(2C), and the percentage of apoptotic cells was determined by tetrametylrodamine methyl ester (TMRM) staining 5 and 7 days after infection. 
Cell morphology of BCL2A1- and mock shRNA–transduced TS cells is shown in the inset. These findings are representative of 3 independent 
experiments. (C–E) BCL2A1 expression correlates with ALK signaling. (C) The expression of BCl2 family genes was evaluated in all experi-
mental conditions (33 samples) for absolute correlation with AlK. The BCl2A1 gene clustered within the branch including the AlK probe set 
(green rectangle). (D) BCl2A1 mRNA expression is significantly downmodulated after ALK RNAi. mRNA expression levels were assessed by 
microarray analysis of ALK-knockdown experiments in TS and Su-DHL1 cells. (E) Loss of ALK expression leads to the BCL2A1 protein down-
regulation. TS-TTA and Su-DHL1-TTA cells transduced with A5 or A5M were treated with DOX (84 hours). Western blot analysis was carried 
out on whole-cell lysates with antibodies against BCL2A1 and ALK.
Downloaded from http://www.jci.org on July  1, 2015.   http://dx.doi.org/10.1172/JCI29401
research article






















CEBPB is an NPM-ALK and STAT3 target gene. (A) Identification of genes whose expression strongly correlated with TNFRSF8 expression. 
Genes from the list obtained by the supervised analysis of TS-TTA-A5 (untreated+A1) versus A2+A3 cells (268 genes) were hierarchically 
clustered in all experimental conditions (33 samples). The plot represents a portion of the list, which includes transcripts with the highest degree 
of correlation to TNFRSF8 expression (green rectangle). (B) CEBPB expression is correlated with TNFRSF8. TNFRSF8 and CEBPB mRNA 
expression levels are represented in the histogram as assessed by microarray analysis of 12 TS-TTA-A5 samples. The statistical significance 
was ranked according to the z score. (C) C/EBPβ protein expression is strongly repressed following NPM-ALK silencing. TS-TTA and Su-DHL1-
TTA cells were transduced with A5 or A5M and treated with DOX (84 hours). Western blot analysis was carried out on whole-cell lysates with 
specific antibodies, as indicated. Different bands represent multiple C/EBPβ isoforms. (D) STAT3 and ERK1/ERK2 regulate C/EBPβ expression. 
TS-TTA cells were transduced with pLVTH-STAT3, pLVTH-ERK1 and pLVTH-ERK2, pLVTH-AKT1, or pLVTH-PLC-γ shRNA interfering con-
structs and treated with DOX (96 hours). Western blot analysis was carried out on whole-cell lysates with the specified antibodies. (E) C/EBPβ 
protein expression is restricted to ALK-positive ALCL cell lines. C/EBPβ and NPM-ALK expression was determined by Western blot analysis on 
a panel of lymphoma/leukemia cell lines. α-Tubulin protein expression was included for protein normalization.
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specific, we  transduced  2  addi-

































C/EBPβ is required for ALK-mediated transformation and tumor growth. (A and B) Downregulation of 
C/EBPβ expression by RNAi. TS cells were transduced with lentivirus (pLKO-GFP) expressing control 
(4C) or 4 C/EBPβ-directed shRNAs (10A–D). C/EBPβ mRNA and protein expression were determined by 
RT-PCR (A) and Western blot (B) analyses (96 hours). As a control, β2-microglobulin mRNA, α-tubulin, 
and phospho-eIF2α protein expression was documented. (C and D) C/EBPβ knock down compromises 
viability of ALCL cells in vitro. (C) TS cells were transduced with the indicated shRNA lentivirus. Percent-
age of apoptotic cells (sub-G0/G1) was determined by PI staining at day 5. (D) ALK-positive ALCL (TS, 
Su-DHL1, and JB) and ALK-negative (MAC-1 and K-562) cell lines were transduced with C/EBPβ (10D) 
or mock shRNA constructs. Apoptotic cells were determined at day 7. These findings are representative 
of 3 independent experiments. Error bars indicate SD. (E and F) C/EBPβ expression is required for tumor 
growth of ALK-positive cells in vivo. WT and c/ebpb–/– MEFs were transduced with a retrovirus express-
ing EGFP/NPM-ALK. NPM-ALK, C/EBPβ, and α-tubulin protein expression was determined by Western 
blotting (E) prior to subcutaneous inoculation (5 × 105 cells/mouse) into 8 athymic nu/nu mice recipients. 
Tumor growth was monitored over time (F). Error bars indicate SD.
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Analysis of apoptosis by flow cytometry. Apoptosis was measured by flow cytome-
try after staining with annexin V or tetrametylrodamine methyl ester (TMRM). 
Annexin V binding was revealed by incubation with streptavidin-PE (11).
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skin tumorigenesis involving oncogenic Ras signal-
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